# Regeneron Pharmaceuticals (REGN) Forecast Calculator

Interactive five-year financial forecast and DCF for Regeneron Pharmaceuticals. Adjust revenue growth, margins, capex, and WACC to update revenue, free cash flow, and enterprise value.

- Canonical: https://finamodel.com/companies/regeneron-pharmaceuticals/forecast
- Industry: Healthcare
- Forecast start year: 2026

## Historical data

| Year | Revenue | Free cash flow | EBITDA | Net income |
|---:|---:|---:|---:|---:|
| 2021 | 6557600000 | 2000400000 | 2420100000 | 2115800000 |
| 2022 | 8497100000 | 2003500000 | 3812500000 | 3513200000 |
| 2023 | 16071700000 | 6529400000 | 9233000000 | 8075300000 |
| 2024 | 12172900000 | 4424800000 | 5080300000 | 4338400000 |
| 2025 | 13117200000 | 3875400000 | 4468100000 | 3953600000 |

## Frequently asked questions

### What does Regeneron Pharmaceuticals do?

Regeneron Pharmaceuticals is a fully integrated biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious diseases. The company operates through a hybrid business model, generating revenue from direct product sales in the US and highly lucrative profit-sharing collaborations globally.

### How does Regeneron Pharmaceuticals generate its revenue?

Regeneron generates revenue primarily through Net Product Sales in the US and significant profit-sharing collaborations. The Sanofi Collaboration, largely driven by Dupixent, accounts for approximately 37% of revenue, while the Bayer Collaboration contributes about 10% from ex-US EYLEA sales.

### What are Regeneron's capital expenditure trends?

Regeneron's capital expenditure is historically high for a biotech company, running between $850 million and $975 million annually, representing 6-7% of revenue. Approximately 80% of this capex is growth-related, driven by significant investments in new fill-finish facilities and biologics manufacturing expansions.

### What is Regeneron's working capital profile?

Regeneron maintains a positive net working capital, primarily due to substantial cash balances and receivables from highly rated pharmaceutical partners. The company has a DIO of 150-180 days due to long biologics manufacturing lead times, while DSO is 45-55 days and DPO is 30-40 days.

### What is the primary purpose of the Regeneron financial model?

The Regeneron financial model projects the company's sum-of-the-parts cash flows to determine its equity valuation. Specifically, it assesses whether the rapid growth from the Sanofi collaboration (Dupixent) and the transition to EYLEA HD can successfully counteract revenue erosion from EYLEA biosimilar competition.

### Can I download an Excel financial model for Regeneron Pharmaceuticals?

Yes, a downloadable Excel financial model is available for Regeneron Pharmaceuticals (REGN). This general corporate model forecasts the company's financials from FY2026 to FY2030, incorporating key assumptions like revenue growth and margin percentages.